Radiopharmaceutical Therapy 2023

Radiopharmaceutical therapies (RPTs) are increasingly utilized for treatment of prostate, neuroendocrine, thyroid and other cancers. Radiation oncologists are experts regarding the benefits and risks associated with various cancer radiotherapeutic options and are thus uniquely positioned to evaluate radiation treatment options for patients, including the use of RPTs. Radiation oncologists are designated authorized users for RPTs, but do not frequently prescribe RPTs or pursue development of RPT programs due to lack of training, infrastructure and knowledge of how to establish a program. The lack of training may affect patient safety and access to care, especially for new therapeutic radiopharmaceuticals since few practitioners are actively developing the RPT programs in the country.

The course includes didactic presentation from physician experts from radiation oncology, nuclear medicine, medical oncology and medical physicists, with question-and-answer sessions to discuss practice implementation in various clinical settings (i.e. academic hospital vs community practice, nuclear medicine vs radiation oncology).

The purpose of the course is to increase physician, physicist, billing and administration understanding on how to effectively and safely develop a radiopharmaceutical program at their respective institutions.

This activity is available from January 16, 2024, through 11:59 p.m. Eastern time on December 31, 2024.

This activity was originally recorded at the 2023 ASTRO Annual Meeting on September 30, 2023. 

Target Audience

The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation physicists, radiation therapists, medical oncologists and other specialists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate radiation treatment options for patient use such as radiopharmaceutical therapies.
  • Safely and effectively administer the new and growing list of active radiopharmaceuticals.
  • Actively establish and develop radiopharmaceutical therapy programs for patient care.
Course summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 4.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 4.50 Certificate of Attendance
    This activity was designated for 4.50 AMA PRA Category 1 Credit™.
Course opens: 
01/10/2024
Course expires: 
12/31/2024
Cost:
$379.00
Rating: 
0

1) Introduction to Radiopharmaceutical Therapies (RPTs) and Basic Radiobiology of RPTs

2) Basic Physics and Radiobiology of RPTs

3) Y90 Radioembolization in the Management of Primary and Metastatic Liver Malignancies

4) Evolving Role of PSMA Imaging in the Management of Prostate Cancer

5) The Treatment Landscape for mCRPC: Radium 223, Lu-177 PSMA and Future of RLT

6) Lu-177 PSMA Therapy: Developing the Standard Operating Procedure

7) Radiopharmaceutical Therapy Case Presentation and Discussion

8) Lu-177-Dotatate (NET): Clinical Indications

9) Practical Considerations and Post-Therapy Dosimetry for Lu-177 Dotatate

10) Case Presentation and Discussion

Moderators:

  • Hyun Kim, MD, Washington University School of Medicine in St. Louis, Department of Radiation Oncology, St. Louis, MO
    • Employed by Washington University School of Medicine. Dr. Kim receives research funding from Varian and ViewRay. Dr. Kim receives compensation from Novartis. Dr. Kim has limited liability company interest with GlobalART as the Founder/CEO. Dr. Kim serves as Associate Editor on the GI Editorial Board of IJROBP. 
  • Richard Glenn Stock, MD, Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
    • Employed by Icahn School of Medicine at Mount Sinai. 
  • Jacqueline Esthappan Zoberi, PhD, Washington University School of Medicine, Department of Radiation Oncology, St. Louis MO
    • Employed by Washington University School of Medicine, Department of Radiation Oncology.  

Speakers:

  • Ana P. Kiess, MD, PhD, is employed by the Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine. Dr. Kiess receives research funding from Novartis/AAA, Bayer and Merck. Dr. Keiss is an Oral Board examiner/volunteer section member of the American Board of Radiology. 
  • Steven Graves, PhD, is employed by the University of Iowa. Dr. Graves receives compensation from CDE Dosimetry Inc. and receives honoraria from Novartis and Voximetry. 
  • Navesh K. Sharma, DO, PhD, is employed by WellSpan Medical Group. Dr. Sharma receives honoraria from Sirtex Medical. 
  • Bridget F. Koontz, MD, FASTRO, is employed by GenesisCare USA. Dr. Koontz is an Adjunct Volunteer Affiliate Professor with East Carolina University. Dr. Koontz receives research funding and sits on the Board of Directors with Rythera Therapeutics, compensation from Blue Earth Diagnostics, and honoraria from Lantheus. Dr. Koontz serves as Co-chair of the Ancillary Projects Committee of NRG Oncology. 
  • William Oh, MD, is employed by Icahn School of Medicine at Mount Sinai. Dr. Oh receives compensation from Genetic Chemistry Therapeutics, Pfizer and the Prostate Cancer Foundation where he serves as CMO. Dr. Oh receives royalties as an author with Up-to-Date. Dr. Oh owns stock options in Sema4/GeneDx. 
  • Vikas Prasad, MD, PhD, is employed by Washington University School of Medicine in St. Louis. Dr. Prasad serves as Dean with the ICPO Centre of Excellence and is Chair of the Theranostics Task Force with the European Neuroendocrine Tumor Society. 
  • Justin Mikell, PhD, is employed by Washington University School of Medicine in St. Louis. 

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
Committee Disclosures

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

Available Credit

  • 4.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 4.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 4.50 Certificate of Attendance
    This activity was designated for 4.50 AMA PRA Category 1 Credit™.

Price

Cost:
$379.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

Nonmember: $379
Member: $249
Member-in-training: $129

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until December 31, 2024, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.